Mr. Robert Alexander, PA-C Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 7300 North Perimeter Road, 341 Medical Group/sghq, Malmstrom Afb, MT 59402 Phone: 406-632-4448 |
Christine Hong, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 7300 N Perimeter Rd, Malmstrom Afb, MT 59402 Phone: 406-731-3177 |
Joyanne Tesei, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 7300 N Perimeter Rd, Malmstrom Afb, MT 59402 Phone: 064-731-2110 |
Noah Russell, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 7300 N Perimeter Rd, Malmstrom Afb, MT 59402 Phone: 406-731-4432 |
Mr. Timothy Paul Gacioch, PA Physician Assistant - Medical Medicare: Medicare Enrolled Practice Location: 4300 Perimeter Rd, (341st Med Group) Bldg 2040, Room S156, Malmstrom Afb, MT 59402 Phone: 406-731-2928 |
Maggie Lea Dutcher, PA-C Physician Assistant - Medical Medicare: Medicare Enrolled Practice Location: 7300 N Perimeter Rd, Malmstrom Afb, MT 59402 Phone: 406-731-4633 |
Maren Elayna Smith, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 7300 N Perimeter Rd, Malmstrom Afb, MT 59402 Phone: 406-731-3573 |
Sara Kathryn Daniel, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 7300 N Perimeter Rd, Malmstrom Afb, MT 59402 Phone: 406-731-4448 |
Collin Urbanowicz, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 7300 N Perimeter Rd, Malmstrom Afb, MT 59402 Phone: 406-731-4633 |
Mr. Alexander Ortiz, Physician Assistant Medicare: Medicare Enrolled Practice Location: 7300 N Perimeter Rd, Malmstrom Afb, MT 59402 Phone: 406-731-2355 |
Alberto Ordonez Iii, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 7300 N Perimeter Rd, Malmstrom Afb, MT 59402 Phone: 406-731-4633 |
News Archive
The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.
Since October 2014 the Ebola epidemic in West Africa has been diminishing and efforts have shifted from emergency response to prevention and mitigation of future outbreaks. Researchers from the Liberian Ministry of Health and the Yale Center for Infectious Disease Modelling and Analysis evaluated 3532 Ebola cases reported in 2014 in order to quantify the impact of poverty on the transmission and spread of Ebola.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority and Ethics Committee approval for Rexahn's initial Clinical Trial Application.
Treatment with an agent that blocks the oxidation of an important component of the mitochondrial membrane prevented the secondary damage of severe traumatic brain injury and preserved function that would otherwise have been impaired, according to a research team from the University of Pittsburgh School of Medicine, Graduate School of Public Health and Department of Chemistry in a report published online today in Nature Neuroscience.
› Verified 5 days ago